|Bid||14.69 x 500|
|Ask||14.70 x 200|
|Day's Range||14.54 - 14.76|
|52 Week Range||4.41 - 16.60|
|PE Ratio (TTM)||-10.02|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Amicus Therapeutics CEO John Crowley on how his fight to find a cure for his children's rare disease, Pompe, has driven his work in the pharmaceutical industry.
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Biotech stocks narrowed in on a 21-month high Wednesday with big rises coming from the likes of Intercept, Amicus and Exelixis on positive drug and partnership news.
Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD ) were trading higher by more than 12 percent Wednesday after the company released encouraging clinical trial data. The company's therapy showed a greater ...
Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline. Amicus's shares rose as much as 6 percent in morning trading, recovering from a nearly 15 percent slide before the bell.
U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial. The company said its drug, when compared with a placebo, ...
Amicus Therapeutics (FOLD) needs Investors to pay close attention to the stock based on moves in the options market lately.
Amicus' stock continues to benefit from its emerging rare disease pipeline and the industrywide upswing in biotech valuations this year.
The Food and Drug Administration changed its tune on Amicus' lead drug, and shareholders couldn't be happier.
The Cranbury, New Jersey-based company said it had a loss of 34 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
After an about-face at the FDA sent shares soaring earlier this week, management announced a stock offering to bolster its balance sheet.
Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.